AI assistant
NovoCure Ltd — Director's Dealing 2018
Jun 21, 2018
31949_dirs_2018-06-21_5c8caf64-5936-4a44-97a7-0e57dc5b6f50.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2018-06-19
Reporting Person: Danziger Asaf (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-06-19 | Ordinary Shares | S | 621 | $32.00 | Disposed | 147990 | Direct |
| 2018-06-20 | Ordinary Shares | S | 8308 | $32.0351 | Disposed | 139682 | Direct |
Footnotes
F1: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger.
F2: On June 20, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 8,308 shares in multiple trades at prices ranging from $32.00 to $32.20. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.